<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C68B0A0F-8143-4EBB-94DA-884B8820201C"><gtr:id>C68B0A0F-8143-4EBB-94DA-884B8820201C</gtr:id><gtr:name>United Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C68B0A0F-8143-4EBB-94DA-884B8820201C"><gtr:id>C68B0A0F-8143-4EBB-94DA-884B8820201C</gtr:id><gtr:name>United Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BD6339DF-6706-4458-ACAD-49C246900497"><gtr:id>BD6339DF-6706-4458-ACAD-49C246900497</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>F</gtr:otherNames><gtr:surname>Dominiczak</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13063"><gtr:id>64FDE121-A03D-44F9-BCC4-94A9BB36AE55</gtr:id><gtr:title>UoGlasgow Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13063</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>500000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>United Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>miR96 and pulmonary hypertension</gtr:description><gtr:id>5F338051-297A-4AF0-A3B5-214EDA7AD5A6</gtr:id><gtr:impact>Too early</gtr:impact><gtr:outcomeId>58b034ba842080.05395711-1</gtr:outcomeId><gtr:partnerContribution>Provision of &amp;pound;79000 to cover costs of a patent and RNAseq</gtr:partnerContribution><gtr:piContribution>Building on our success with the MRC CiC award and the PhD studentship we were awarded a MRC project grant to further our studies into miR96 and PAH. This created discussions with United Therapeutics who supplemented tis study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Scottish HPV Investigators Network (SHINe)</gtr:department><gtr:description>SHINe</gtr:description><gtr:id>65189C7D-2885-4133-A9BD-E9477D7667CC</gtr:id><gtr:impact>Funding for an MRC Clinical Training Fellow. Two papers in submission. A grant application in preparation</gtr:impact><gtr:outcomeId>ZLoD3Q8CjEc-1</gtr:outcomeId><gtr:partnerContribution>Discussions, clinical material, new projects initiated</gtr:partnerContribution><gtr:piContribution>I am a member of this consortium</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public engagement</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C2ACE5B-F591-4E68-AF46-509D72A14820</gtr:id><gtr:impact>We and our group members have been involved in Explorathon events and organised interactive workshops during &amp;quot;Science Weeks&amp;quot;, for example at SU and the Glasgow Science Centre, the latter focusing on a 'Drugs from Bugs, ask Dr. Worm' event, designed to involve both children and parents in our research. Relating to this, further interaction with the public is encouraged by our ES-62 website (ES62.webstarts.com) and Facebook page (&amp;quot;Drugs from Bugs&amp;quot;), which focus on educational and translational aspects of research employing parasitic worms and we are scheduled to provide our interactive workshop to local primary 4/5 school children in April 2016.</gtr:impact><gtr:outcomeId>56d733860eb773.34962941</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://ES62.webstarts.com</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Centre Meet the Experts events Dundee &amp; Glasgow</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>88562047-1014-4656-9876-76BF63D02FF7</gtr:id><gtr:impact>Members of our group including the PDRA (JC) on the award participated in interactive workshops at the Dundee and Glasgow Science Centres for 5th and 6th secondary school pupils focusing on the Hygiene Hypothesis and therapeutic potential of parasitic worm products, and drugs based on these, in inflammatory disease and potentially on life/healthspan.</gtr:impact><gtr:outcomeId>58b86375204d05.44196715</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk - MD Anderson Centre, Houston, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>06776D75-6A02-4CBB-97EC-2CB0472BA7D0</gtr:id><gtr:impact>Lecture as part of the Haematology Grand Round at the MD Anderson Centre, Houston</gtr:impact><gtr:outcomeId>58ac674a9f67e9.14084702</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>38FB54F2-6B66-4652-81E8-23B46C6004B2</gtr:id><gtr:impact>We and our group members are active in interacting with the public via our ES-62 website (ES62.webstarts.com), Facebook page (&amp;quot;Drugs from Bugs&amp;quot;) and @HarnettLabsTwitter account, all of which focus on educational and translational aspects of research employing parasitic worms in inflammatory disease. Moreover, we have just presented our interactive workshop 'Drugs from Bugs, ask Dr. Worm' to &amp;gt;50 local primary 4/5 school children (May 2016)</gtr:impact><gtr:outcomeId>57347afd897ee6.63495200</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Portugal</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C27E711-A6A4-49CF-A033-AE4D2915BC48</gtr:id><gtr:impact>Talk with discussion

improved collaborations</gtr:impact><gtr:outcomeId>545a461a5427e4.37742064</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH, Estoril</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCD48F6D-24D5-42D3-A55A-925982E07520</gtr:id><gtr:impact>Keynote Lecturer at the European Society of Haematology, Estoril, Portugal</gtr:impact><gtr:outcomeId>56c3287bf184c8.97687015</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Till and McCulloch meeting, Toronto</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B2BCE424-66AF-44C2-B370-5B96C434917B</gtr:id><gtr:impact>Guest speaker at the Till and McCulloch meeting, Toronto, Canada</gtr:impact><gtr:outcomeId>56c328fc905a34.16301554</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA, Vienna</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C858226-4EE3-4A81-A6E0-D4CA42B37BA9</gtr:id><gtr:impact>Speaking at European Haematology Association Meeting in Vienna</gtr:impact><gtr:outcomeId>56c328019a7db1.93863764</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South East Scotland Blood Club meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3CFB7D20-8A6C-4954-B23F-048E752B247F</gtr:id><gtr:impact>talk

opened up discussion</gtr:impact><gtr:outcomeId>545a47450ed025.36031718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem cell symposium Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>02362E00-516D-4A98-8020-235AFB634DCC</gtr:id><gtr:impact>talk and discussion

improved collaboration</gtr:impact><gtr:outcomeId>5462181dc46376.22188402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hinterzarten Circle on Cancer Research, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>12F385C2-ADB8-4A57-8EF9-C6A955999798</gtr:id><gtr:impact>Speaking at annual meeting of the Hinterzarten Circle on Cancer Research of the DFG (German Research Foundation</gtr:impact><gtr:outcomeId>56c32773888b60.71400303</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B968A61-238D-4BED-B153-3AC3960158AE</gtr:id><gtr:impact>Keynote lecture - Course on Molecular Aspects of Haematological Disorders</gtr:impact><gtr:outcomeId>58ac66de15bd87.11385571</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>32000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative research grant</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Roche Pharmaceuticals</gtr:fundingOrg><gtr:id>4DC96548-FFCF-406C-A5C9-277EA84FD3C8</gtr:id><gtr:outcomeId>56e142ff82c481.28423536</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1258477</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N018958/1</gtr:fundingRef><gtr:id>AB9BEBA4-DED7-4AAC-A445-F0E1500A823C</gtr:id><gtr:outcomeId>56d02e6c8cf014.59861231</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRS studentship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:fundingRef>PhD-890-2015</gtr:fundingRef><gtr:id>970D269F-BBAD-4ADA-9921-C8CAB5F2C57F</gtr:id><gtr:outcomeId>56c70f8fb11176.43973338</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>116308</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Scotland PhD studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:fundingRef>PhD-789-2014</gtr:fundingRef><gtr:id>82C9C127-71B2-47FF-857B-0DDB685DDC48</gtr:id><gtr:outcomeId>56c6d28e36f6c7.24302075</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>595086</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N011112/1</gtr:fundingRef><gtr:id>88EF1DCF-7A8B-475C-A65E-B1BEA4802BED</gtr:id><gtr:outcomeId>56a605eeeeec60.01066191</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical Catalyst Feasibility</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS)</gtr:fundingOrg><gtr:fundingRef>Application Number: 81103-511295</gtr:fundingRef><gtr:id>402E3AFF-DD01-4B7B-BCC8-2AFA99D51CE7</gtr:id><gtr:outcomeId>58c2bb6d406278.04678423</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SULSA Hi-Throughput assay development fund.</gtr:description><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>E4227C2B-3964-4694-9308-B2B3F0C883BF</gtr:id><gtr:outcomeId>56e02986c2aff9.85164686</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23540</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/CiC</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>75A1F625-EDA9-488B-839C-B08A5D555F38</gtr:id><gtr:outcomeId>56e04693c87077.06674225</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112164</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC iCASE</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N018230/1</gtr:fundingRef><gtr:id>B549A53C-70B0-4ACE-8130-E043A11DB1C1</gtr:id><gtr:outcomeId>56c70e9a2de612.85196527</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3093480</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Advanced Grant</gtr:description><gtr:end>2022-08-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>B916BCFD-726D-4392-B26E-FA18E6B9D8FB</gtr:id><gtr:outcomeId>58c7d5968b6c16.08044377</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>394000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>High-Growth Spinout Programme</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>09689A82-4FB2-478B-BD22-92251B725098</gtr:id><gtr:outcomeId>58c17807e0c540.11322692</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2020-05-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>Award No. 14033</gtr:fundingRef><gtr:id>9A66E90E-EE66-4F15-AF30-3D9C347EB632</gtr:id><gtr:outcomeId>56e1446534ca27.22526018</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative research funding.</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Constellation Pharmaceuticals</gtr:fundingOrg><gtr:id>2FB869A5-CE72-4FDA-8EC4-7DB44DDE52EB</gtr:id><gtr:outcomeId>56e1429ea37060.04043730</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This relates to ES-62 SMAs and their uses in the treatment or prophylaxis of diseases associated with inflammation.</gtr:description><gtr:grantRef>MC_PC_13063</gtr:grantRef><gtr:id>191A2828-72EC-4600-9423-FAB12264BBC0</gtr:id><gtr:impact>This has now been published in the European (17.06.2015) and USA patent offices (06.08.2015) allowing the therapeutic potential of our SMAs to be evaluated in several indications in partnership with Industry: in particular with Jubilant- India (matched funding from the University of Strathclyde) in Lung Fibrosis, AstraZeneca in Alopecia and Leopharma in Psoriasis.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d8166ed0c115.99703652</gtr:outcomeId><gtr:patentId>WO/2014/023934</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Immunomodulatory compounds</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New technique training to research technician</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>64A4AF63-AA7F-4F8F-895C-2D26FF38D7E1</gtr:id><gtr:impact>The work has fed into development of a clinical trial grant application to CRUK-EMP</gtr:impact><gtr:outcomeId>58c7c4c628f043.92902357</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>submitting clinical trIal grant CRUK EMP 20 March</gtr:description><gtr:id>60B99FE2-AC74-42B3-AE2C-3B81F01F3373</gtr:id><gtr:impact>NOT YET</gtr:impact><gtr:outcomeId>58c7c658c73b97.43669040</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Idasanutlin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>stem cell data including leukaemia stem cells</gtr:description><gtr:id>1A8533F1-29FC-4ACE-8BA0-6F8065F8542E</gtr:id><gtr:impact>Publication in Nature and Cancer Discovery and lots of press release around this</gtr:impact><gtr:outcomeId>58c7c6b8efa4a8.93491713</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>stemformatics</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have been developing a 3D culture system that will be further developed as a model system for human joints in arthritis by MAP in his ARUK-CDF</gtr:description><gtr:id>35414C97-EC4B-4626-923D-68F342CCDDD6</gtr:id><gtr:impact>By developing an in vitro model of mouse and human arthritic joints, this will allow us to screen a large number of SMAs in vitro, obviating the need for a large number of the animal models that we require at present</gtr:impact><gtr:outcomeId>56d814e0dc3198.39728662</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>3D model</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Ability to administrate small molecules to sub-lethally irradiated NSG mice</gtr:description><gtr:id>60BCBB7C-3D38-4E97-A194-0BB6B074AD73</gtr:id><gtr:impact>Set a new level of optimisation for CML in NSG mice</gtr:impact><gtr:outcomeId>58c7c546e54d58.49112163</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New in-vivo approaches in xenograft mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9AA52C4F-37B4-4104-A290-821D5A352A42</gtr:id><gtr:title>Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function post-myocardial infarction via a direct inotropic effect</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2890053faf10c83a6a6a7c0b6cb26634"><gtr:id>2890053faf10c83a6a6a7c0b6cb26634</gtr:id><gtr:otherNames>Fattah C</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56b06b0e950649.10189005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AE692BB-6EF7-4348-B921-9887E194C401</gtr:id><gtr:title>The chronic myeloid leukemia stem cell: stemming the tide of persistence.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9971b356a7b47c06716ecaedfc78dca8"><gtr:id>9971b356a7b47c06716ecaedfc78dca8</gtr:id><gtr:otherNames>Holyoake TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58ac5377270ff1.20928207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E05B241-26C6-4189-90D6-48B1D546EDCB</gtr:id><gtr:title>Preclinical approaches in chronic myeloid leukemia: from cells to systems.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aeabcd4ae4e875e598fdac6506e39c8"><gtr:id>1aeabcd4ae4e875e598fdac6506e39c8</gtr:id><gtr:otherNames>Clarke CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn><gtr:outcomeId>58ac537748f6b3.59048751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEE64333-B132-4258-9C86-0CDEA4FD3934</gtr:id><gtr:title>Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1? production via NRF2-mediated counter-regulation of the inflammasome.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9100021fd5df96d8dce8cb471b8b3c2e"><gtr:id>9100021fd5df96d8dce8cb471b8b3c2e</gtr:id><gtr:otherNames>Rzepecka J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>56d5696cd4bc87.34691654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8658585B-6E42-4418-9AAC-5F86456A9E55</gtr:id><gtr:title>Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2890053faf10c83a6a6a7c0b6cb26634"><gtr:id>2890053faf10c83a6a6a7c0b6cb26634</gtr:id><gtr:otherNames>Fattah C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>588b62b5870f52.32113627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827F13EF-2E6D-48EF-8A00-4B8F1ABA9BAD</gtr:id><gtr:title>Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c2579369e6ecc4d9f02aff026f1813e"><gtr:id>0c2579369e6ecc4d9f02aff026f1813e</gtr:id><gtr:otherNames>Lumb FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a7864204fb405.29762839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7967FBDE-72AB-4393-9E78-E75FBD3EAD51</gtr:id><gtr:title>Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b201cb4f4a74f892d1c17469eab72247"><gtr:id>b201cb4f4a74f892d1c17469eab72247</gtr:id><gtr:otherNames>Rodgers DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a786420c4a7e5.36587164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A127110-A90A-485F-83EC-32F902F02CF0</gtr:id><gtr:title>Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44701d76135ad7a45126aa81a11d96bc"><gtr:id>44701d76135ad7a45126aa81a11d96bc</gtr:id><gtr:otherNames>Abraham SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58ac5378787e72.00104598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F31EA2A-EDD7-446F-8160-435CBBBA5260</gtr:id><gtr:title>Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d379558bbb697f89493d1c077ec688"><gtr:id>11d379558bbb697f89493d1c077ec688</gtr:id><gtr:otherNames>McCaughey LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d6b12cf3e02.02616088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F324217-44DF-450B-B8F6-193C07854C24</gtr:id><gtr:title>Discovery, characterization and in&amp;nbsp;vivo activity of pyocin SD2, a protein antibiotic from Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d379558bbb697f89493d1c077ec688"><gtr:id>11d379558bbb697f89493d1c077ec688</gtr:id><gtr:otherNames>McCaughey LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>58c1763595cff0.63882797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C3EF82A-2350-4CC8-8647-08FFEE1EBFCF</gtr:id><gtr:title>A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5244001dfe16285932a55c85749d05c0"><gtr:id>5244001dfe16285932a55c85749d05c0</gtr:id><gtr:otherNames>Wallace E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56a5fffd629306.84249180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB5A0DAE-C153-459A-839C-3C966A5C0A97</gtr:id><gtr:title>Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation.</gtr:title><gtr:parentPublicationTitle>Experimental parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f84753c4001c701db42f46451692dc7"><gtr:id>0f84753c4001c701db42f46451692dc7</gtr:id><gtr:otherNames>Al-Riyami L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-4894</gtr:issn><gtr:outcomeId>5a786420e71194.60260653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>567DBD0D-4A05-4F70-892C-7A425D0277D0</gtr:id><gtr:title>Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1? production via NRF2-mediated counter-regulation of the inflammasome.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9100021fd5df96d8dce8cb471b8b3c2e"><gtr:id>9100021fd5df96d8dce8cb471b8b3c2e</gtr:id><gtr:otherNames>Rzepecka J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>5aa68597c674d9.66206844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>683C2B02-8BC4-4170-822D-253671D79847</gtr:id><gtr:title>The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bf11e982af457c1a1950f30187706f6"><gtr:id>6bf11e982af457c1a1950f30187706f6</gtr:id><gtr:otherNames>Coltherd JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a7864207b1ee7.25466462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12E3E196-E48B-487D-823E-03CEDFAD02BE</gtr:id><gtr:title>Casting a NETwork instead of shooting magic bullets.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44701d76135ad7a45126aa81a11d96bc"><gtr:id>44701d76135ad7a45126aa81a11d96bc</gtr:id><gtr:otherNames>Abraham SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>58ac5378082c84.21791327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB7BF7A4-A9EC-4D54-84DC-A5D8B7DCF7AB</gtr:id><gtr:title>Stroke With Unknown Time of Symptom Onset: Baseline Clinical and Magnetic Resonance Imaging Data of the First Thousand Patients in WAKE-UP (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke: A Randomized, Doubleblind, Placebo-Controlled Trial).</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb32e6ec4a879d6c43c899d32a468035"><gtr:id>fb32e6ec4a879d6c43c899d32a468035</gtr:id><gtr:otherNames>Thomalla G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>5aa02f6f4e8ca4.93190543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E26DBA9-A36F-48F1-8976-5AB35EDFBF34</gtr:id><gtr:title>Stem Cell Guardians - Old and New Perspectives in LSC Biology.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b63b5b65b3097b2a5034c842ad8f951"><gtr:id>7b63b5b65b3097b2a5034c842ad8f951</gtr:id><gtr:otherNames>Horne GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>58ac5378527527.65295067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB1DBA6-7936-448F-8695-AF0F123DC17D</gtr:id><gtr:title>Testing small molecule analogues of the Acanthocheilonema viteae immunomodulator ES-62 against clinically relevant allergens.</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b365a1126c2e09e49d09d1750029575"><gtr:id>3b365a1126c2e09e49d09d1750029575</gtr:id><gtr:otherNames>Janicova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>5a7864e7cf3981.49030290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C347DC16-A9C5-44EA-B781-4FD6A6EEC71B</gtr:id><gtr:title>195 Angiotensin-(1-9) Reduces Cardiac Dysfunction in a Model of Angiotensin II-Induced Hypertensive Heart Disease</gtr:title><gtr:parentPublicationTitle>Heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df79e304e8c907dc62a0ddb0ceb2f15"><gtr:id>3df79e304e8c907dc62a0ddb0ceb2f15</gtr:id><gtr:otherNames>Nather K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b06e97221c19.40003481</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13063</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>